7 research outputs found
ΠΠ°ΡΡΠΆΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° Π² Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅: ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π²ΡΠ·ΠΎΠ²Ρ ΠΈ ΠΎΡΠ²Π΅ΡΡ
Atopic dermatitis (AD) is the most prevalent skin disease in the early childhood and is a considerable problem both for patients and members of their families and for the society on the whole. In most cases, AD requires a long-term therapy such as the use of anti-inflammatory drugs. Selective inhibitors of the synthesis and release of proinflammatory cytokines - topical calcineurin inhibitors (Tcis) - are now used to solve this problem, with pimecrolimus being one of them. Pimecrolimus has been thoroughly examined for the past decade in different clinical studies involving a total of over 4,000 infants (below 2 years of age). These studies demonstrated the efficacy and safety of pimecrolimus for AD in children provided it is used in a long-term therapy on an intermittent basis. Unlike topical corticosteroids, the long-term use of pimecrolimus is not associated with any risk of development of systemic immunosuppression, skin atrophy, skin barrier dysfunction or systemic absorption so it is safe even if applied to the most sensitive skin areas. In view of this, the authors make a conclusion that pimecrolimus used in the form of a cream is a safe and efficient drug for the treatment of infants aged over three months suffering from atopic dermatitis.ΠΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΉ Π΄Π΅ΡΠΌΠ°ΡΠΈΡ (ΠΠ) ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΌΡΠΌ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΆΠΈ Π² ΡΠ°Π½Π½Π΅ΠΌ Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ ΠΊΠ°ΠΊ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΠ»Π΅Π½ΠΎΠ² ΠΈΡ
ΡΠ΅ΠΌΠ΅ΠΉ, ΡΠ°ΠΊ ΠΈ Π΄Π»Ρ ΠΎΠ±ΡΠ΅ΡΡΠ²Π° Π² ΡΠ΅Π»ΠΎΠΌ. Π Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² ΠΠ ΡΡΠ΅Π±ΡΠ΅Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ². ΠΠ»Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΡΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΡΠΈΠ½ΡΠ΅Π·Π° ΠΈ Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² - ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Π° (Π’ΠΠ), ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΊΠΎΡΠΎΡΡΡ
ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡ. Π ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π³ΠΎ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡ Π±ΡΠ» ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎ ΠΈΠ·ΡΡΠ΅Π½ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Ρ ΡΡΠ°ΡΡΠΈΠ΅ΠΌ Π² ΠΎΠ±ΡΠ΅ΠΉ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ Π±ΠΎΠ»Π΅Π΅ 4000 Π΄Π΅ΡΠ΅ΠΉ ΡΠ°Π½Π½Π΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° (ΠΌΠ»Π°Π΄ΡΠ΅ 2 Π»Π΅Ρ). Π ΡΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Π±ΡΠ»ΠΈ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡΠ° Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΠ Ρ Π΄Π΅ΡΠ΅ΠΉ ΠΏΡΠΈ ΡΡΠ»ΠΎΠ²ΠΈΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΠΈΠ½ΡΠ΅ΡΠΌΠΈΡΡΠΈΡΡΡΡΠ΅ΠΌ ΡΠ΅ΠΆΠΈΠΌΠ΅. Π ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄ΠΎΠ² Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡΠ° Π½Π΅ ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΈΠΈ, Π°ΡΡΠΎΡΠΈΠΈ ΠΊΠΎΠΆΠΈ, Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π±Π°ΡΡΠ΅ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΊΠΎΠΆΠΈ ΠΈΠ»ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ Π°Π±ΡΠΎΡΠ±ΡΠΈΠ΅ΠΉ ΠΈ, ΡΠ°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎ ΠΏΡΠΈ Π½Π°Π½Π΅ΡΠ΅Π½ΠΈΠΈ Π΄Π°ΠΆΠ΅ Π½Π° ΡΠ°ΠΌΡΠ΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΡΠ°ΡΡΠΊΠΈ ΠΊΠΎΠΆΠΈ. ΠΡΡ
ΠΎΠ΄Ρ ΠΈΠ· ΡΡΠΎΠ³ΠΎ Π°Π²ΡΠΎΡΡ Π΄Π΅Π»Π°ΡΡ Π²ΡΠ²ΠΎΠ΄ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡ Π² Π²ΠΈΠ΄Π΅ ΠΊΡΠ΅ΠΌΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΠΌ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠ΅ΠΉ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΡΡΠ°ΡΡΠ΅ ΡΡΠ΅Ρ
ΠΌΠ΅ΡΡΡΠ΅Π², ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ
ΠΠΈΡΠ΅Π²Π°Ρ Π°Π»Π»Π΅ΡΠ³ΠΈΡ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΌ Π±ΡΠ»Π»Π΅Π·Π½ΡΠΌ ΡΠΏΠΈΠ΄Π΅ΡΠΌΠΎΠ»ΠΈΠ·ΠΎΠΌ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
Background: Inherited epidermolysis bullosa (EB) refers to a group of rare inherited disorders characterized by severe damage of skin and in most patients β the gastrointestinal mucosa, what leads to a violation of skin and mucosal barrier properties in relation to allergens. However, the issues of food sensitization and food allergy in this category of patients have not been studied, and the study of this problem is important.Aim: To evaluate the clinical manifestations of food allergy (FA) and IgE-response to food proteins in children with EB.Methods: 82 patients with EB aged from 2 months to 16 years were entered this open non-randomized observational prospective study, including 20 patients with simple form of EB and 62 patients with dystrophic form of EB. We analyzed allergic history and clinical manifestations of the FA in all the patients. Every patient in this study underwent of determination of the concentration of total serum IgE and specific serum IgE to the most important food allergens, as well as to mixtures of household allergens in some cases (UniCAP System, Phadia AB).Β Results:Β Skin lesion in patients with EB masks allergic skin manifestations, causing a hypodiagnosis of the FA in this category of patients, which in turn leads to erroneous organization of nutritional support. FA (clinical manifestations) was identified in 20.7% of children with EB (in 10% of cases with simple form of EB and in 24.2% β in patients with dystrophic form of EB). Products containing cowβs milk protein, cereals, and eggs were identified as etiologic factors of FA in most cases. In the group of children with comorbidity FA and EB high and very high levels of total IgE (1000 kUA / l) were detected most frequently. The main cause-significant allergens are cowβs milk proteins, cereals, eggs.Β Conclusions: Comorbidity with FA is high in patients with dystrophic form of EB. The main cause-significant allergens are cowβs milk proteins, cereals, eggs.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. ΠΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΉ Π±ΡΠ»Π»Π΅Π·Π½ΡΠΉ ΡΠΏΠΈΠ΄Π΅ΡΠΌΠΎΠ»ΠΈΠ· (ΠΠΠ) ΠΎΡΠ½ΠΎΡΠΈΡΡΡΒ ΠΊΒ Π³ΡΡΠΏΠΏΠ΅ ΡΠ΅Π΄ΠΊΠΈΡ
Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ
ΡΡ ΡΡΠΆΠ΅Π»ΡΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΆΠ½ΡΡ
ΠΏΠΎΠΊΡΠΎΠ²ΠΎΠ²Β ΠΈ ΡΒ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π±ΠΎΠ»ΡΠ½ΡΡ
Β β ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎ-ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°, ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΒ ΠΊΒ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΈΡ
Π±Π°ΡΡΠ΅ΡΠ½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡΒ ΠΊΒ Π°Π»Π»Π΅ΡΠ³Π΅Π½Π°ΠΌ. ΠΠ΄Π½Π°ΠΊΠΎ Π²ΠΎΠΏΡΠΎΡΡ ΠΏΠΈΡΠ΅Π²ΠΎΠΉ ΡΠ΅Π½ΡΠΈΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈΒ ΠΈΒ ΠΏΠΈΡΠ΅Π²ΠΎΠΉ Π°Π»Π»Π΅ΡΠ³ΠΈΠΈΒ ΡΒ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ,Β ΠΈΒ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ.Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΒ β ΠΎΡΠ΅Π½ΠΈΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΠΏΠΈΡΠ΅Π²ΠΎΠΉ Π°Π»Π»Π΅ΡΠ³ΠΈΠΈ (ΠΠ)Β ΠΈΒ ΡΠ΅Π½ΡΠΈΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈΒ ΠΊΒ ΠΏΠΈΡΠ΅Π²ΡΠΌ Π±Π΅Π»ΠΊΠ°ΠΌΒ ΡΒ Π΄Π΅ΡΠ΅ΠΉΒ ΡΒ ΠΠΠ.Β ΠΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΎΡΠΊΡΡΡΠΎΠ΅ Π½Π΅ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π°ΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅. ΠΠΊΠ»ΡΡΠ΅Π½Ρ 82Β ΡΠ΅Π±Π΅Π½ΠΊΠ°Β ΡΒ ΠΠΠΒ Π²Β Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 2Β ΠΌΠ΅Ρ Π΄ΠΎ 16Β Π»Π΅Ρ,Β Π²Β ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ 20Β Π΄Π΅ΡΠ΅ΠΉΒ ΡΒ ΠΏΡΠΎΡΡΠΎΠΉΒ ΠΈΒ 62Β βΒ ΡΒ Π΄ΠΈΡΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ ΠΠΠ. ΠΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈΡΡ Π°Π»Π»Π΅ΡΠ³ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°ΠΌΠ½Π΅Π·Β ΠΈΒ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΠ; Π²ΡΠ΅ΠΌ Π±ΠΎΠ»ΡΠ½ΡΠΌ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΠ±ΡΠ΅ΠΉ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ IgEΒ Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ, sIgE ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈΒ ΠΊΒ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠΌ ΠΏΠΈΡΠ΅Π²ΡΠΌ Π°Π»Π»Π΅ΡΠ³Π΅Π½Π°ΠΌ, ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡΠΌΒ βΒ ΠΊΒ ΡΠΌΠ΅ΡΡΠΌ Π±ΡΡΠΎΠ²ΡΡ
Π°Π»Π»Π΅ΡΠ³Π΅Π½ΠΎΠ²Β ΡΒ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ UniCAP System, Thermo Fisher Scientific (ΡΠ°Π½Π΅Π΅ Phadia ΠΠ).Β Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠΆΠΈ ΠΏΡΠΈ ΠΠΠ ΠΌΠ°ΡΠΊΠΈΡΡΠ΅Ρ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΠΒ ΡΒ Π΄Π΅ΡΠ΅ΠΉ, ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»ΠΈΠ²Π°Ρ Π³ΠΈΠΏΠΎΠ΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΒ ΡΒ ΡΡΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΠΎΒ Π²Β ΡΠ²ΠΎΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ Π²Π΅Π΄Π΅ΡΒ ΠΊΒ Π½Π΅ΠΏΡΠ°Π²ΠΈΠ»ΡΠ½ΠΎΠΉ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ Π½ΡΡΡΠΈΡΠΈΠ²Π½ΠΎΠΉ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΈ. ΠΠ Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π°Β ΡΒ 20,7% Π΄Π΅ΡΠ΅ΠΉΒ ΡΒ ΠΠΠ (Π²Β 10% ΡΠ»ΡΡΠ°Π΅Π² ΠΏΡΠΈ ΠΏΡΠΎΡΡΠΎΠΉΒ ΠΈ Π²Β 24,2% ΠΏΡΠΈ Π΄ΠΈΡΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΠ΅ ΠΠΠ).Β ΠΒ ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ Π²ΡΡΡΡΠΏΠ°Π»ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΡ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠ΅ Π±Π΅Π»ΠΎΠΊ ΠΊΠΎΡΠΎΠ²ΡΠ΅Π³ΠΎ ΠΌΠΎΠ»ΠΎΠΊΠ°, Π·Π»Π°ΠΊΠΈ, ΡΠΉΡΠ°.Β ΠΒ Π³ΡΡΠΏΠΏΠ΅ Π΄Π΅ΡΠ΅ΠΉΒ ΡΒ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΡΡ ΠΠΒ ΠΈΒ ΠΠΠ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ Π²ΡΡΠΎΠΊΠΈΠ΅Β ΠΈΒ ΠΊΡΠ°ΠΉΠ½Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ ΡΡΠΎΠ²Π½ΠΈ ΠΎΠ±ΡΠ΅Π³ΠΎΒ IgE(1000Β kUA/l).Β ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ΅ΡΠΈΒ ΡΒ Π΄ΠΈΡΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ ΠΠΠ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡΒ ΡΒ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈΒ ΡΒ ΠΏΡΠΎΡΡΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠ°ΡΠ΅ ΠΈΠΌΠ΅ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΠ. ΠΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΠΏΡΠΈΡΠΈΠ½Π½ΠΎ-Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ Π°Π»Π»Π΅ΡΠ³Π΅Π½Π°ΠΌΠΈ ΡΠ²Π»ΡΡΡΡΡ Π±Π΅Π»ΠΊΠΈ ΠΊΠΎΡΠΎΠ²ΡΠ΅Π³ΠΎ ΠΌΠΎΠ»ΠΎΠΊΠ°, Π·Π»Π°ΠΊΠΈ, ΡΠΉΡΠ°.